en-label, proof-of-concept study designed to evaluate the feasibility, safety, and acceptability of a prophylactic fish oil-enriched nutritional supplement (Fresubin Supportan) in patients with head and neck cancer (HNC) undergoing curative-intent chemoradiotherapy (CRT) at the University of Kansas Medical Center. The study involves daily supplementation starting two weeks prior to CRT and continuing throughout CRT, alongside weekly nutrition counseling.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Recruitment rate
Timeframe: Through study completion, approximately 18 months
Adherence Rate
Timeframe: From baseline (Week -2) to 3 months post-chemoradiotherapy
Retention Rate
Timeframe: From baseline (Week -2) to 3 months post-chemoradiotherapy
Adverse Events
Timeframe: From baseline (Week -2) to 3 months post-chemoradiotherapy
Supplement Acceptability
Timeframe: From baseline (Week -2) to 3 months post-chemoradiotherapy
Supplement Discontinuation due to AEs
Timeframe: From baseline (Week -2) through 3 months post-chemoradiotherapy